In vitro fungistatic and fungicidal activities of silver sulfadiazine and natamycin on pathogenic fungi isolated from horses with keratomysis

American Journal of Veterinary Research

Volumn 67, Issue 10, 2006, Pages 1788-1793

  Betbeze, Caroline M ^a   Wu, Ching Ching ^a   Krohne, Sheryl G ^a   Stiles, Jean ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATAMYCIN; SULFADIAZINE SILVER;

ANIMAL DISEASE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CHRYSOSPORIUM; CONTROLLED STUDY; CURVULARIA; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS ISOLATION; FUSARIUM; HORSE; IN VITRO STUDY; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIUM;

ANIMALS; ANTIFUNGAL AGENTS; EYE INFECTIONS, FUNGAL; FUNGI; HORSE DISEASES; HORSES; MICROBIAL SENSITIVITY TESTS; NATAMYCIN; SILVER SULFADIAZINE;

ASPERGILLUS; CHRYSOSPORIUM; CURVULARIA; EQUIDAE; FUNGI; FUSARIUM; PENICILLIUM; SCOPULARIOPSIS;

EID: 33750216415     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.10.1788     Document Type: Article

References (48)

1. Whitley R, Burgess E, Moore C. Microbial isolates of the normal equine eye. Equine Vet J Suppl 1983;2:138-140.
2. Moore CP, Fales W, Whittington P. Bacterial and fungal isolates from Equidae with ulcerative keratitis. J Am Vet Med Assoc 1983;182:600-603.
3. Samuelson D, Andresen T, Gwin R. Conjunctival fungal flora in horses, cattle, dogs, and cats. J Am Vet Med Assoc 1984;184:1240-1242.
4. Moore CP, Heller N, Majors LJ, et al. Prevalence of ocular microorganisms in hospitalized and stabled horses. Am J Vet Res 1988;49:773-777.
5. Brooks DA. Equine ophthalmology In: Gelatt K, ed. Veterinary ophthalmology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999;1083-1087.
6. Andrew SE, Brooks DA, Smith PJ, et al. Equine ulcerative keratomycosis: visual outcome and ocular survival in 39 cases (1987-1996). Equine Vet J 1998;30:109-116.
7. Moore CP, Collins BK, Fales WH. Antibacterial susceptibility patterns for microbial isolates associated with infectious keratitis in horses: 63 cases (1986-1994). J Am Vet Med Assoc 1995;207:928-933.
8. Grahn B, Wolfer J, Keller C, et al. Equine keratomycosis: clinical and laboratory findings in 23 cases. Vet Comp Ophthalmol 1993;3:2-7.
9. Regnier A. Clinical ophthalmic pharmacology and therapeutics. Part 2: antimicrobials, anti-inflammatories, and antiglaucoma drugs. In: Gelatt K, ed. Veterinary ophthalmology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 1999;306-308.
10. Plumb D. Natamycin. In: Veterinary drug handbook. 3rd ed. Ames, Iowa: Iowa State University Press, 1999;668.
11. Foster SC. Fungal keratitis. Infect Dis Clin North Am 1992;6:851-857.
12. Vanden Bossche H, Engelen M, Rochette F. Antifungal agents of use in animal health-chemical, biochemical, and pharmacological aspects. J Vet Pharmacol Ther 2003;26:5-29.
13. Borgsdorf L, Selevan J, Cirgliano M, et al. Natamycin. In: Schwein SL, ed. Drug facts and comparisons. St Louis: Kluwer Health Inc, 2006;1772.
14. O'Day D, Ray W, Head W, et al. Influence of corneal epithelium on the efficacy of topical antifungal agent. Invest Ophthalmol Vis Sci 1984;25:853-859.
15. Johns KJ, O'Day DM. Pharmacologic management of keratomycoses. Surv Ophthalmol 1988;33:178-188.
16. Jones BR. Principles in the management of oculomycosis: XXXI Edward Jackson Memorial Lecture. Am J Ophthalmol 1975;79:719-751.
17. Foster SC, Stefanyszyn M. Intraocular penetration of miconazole in rabbits. Arch Ophthalmol 1979;97:1703-1706.
18. Panda A, Sharma N, Angra SK. Topical fluconazole therapy of Candida keratitis. Cornea 1996;15:373-375.
19. Ball MA, Rebhun WC, Gaarder JE. Evaluation of itraconazole-dimethyl sulfoxide ointment for treatment of keratomycosis in nine horses. J Am Vet Med Assoc 1997;211:199-203.
20. Mohan M, Gupta SK, Kalra VK, et al. Topical silver sulfadiazine - a new drug for ocular keratomycosis. Br J Ophthalmol 1988;72:192-195.
21. Velanovich V, Heggers JP, Robson MC, et al. In vivo comparison of two silver sulfadiazine antimicrobial agents on burn wound infection. J Burn Care Rehabil 1987;8:381-383.
22. Gear AJ, Hellewell TB, Wright HR. A new silver sulfadiazine water soluble gel. Burns 1997;23:387-391.
23. Fox CL. Topical therapy and the development of silver sulfadiazine. Surg Gynecol Obstet 1983;57:82-87.
24. Wright JB, Lam K, Hansen D, et al. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 1999;27:344-350.
25. Wlodkowski TJ, Rosenkranz HS. Antifungal activity of silver sulphadiazine. Lancet 1973;2:739-740.
26. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard NCCLS document M38-A. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2002.
27. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother 1995;39:314-319.
28. Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardization procedure for antifungal susceptibility testing for filamentous fungi. J Chin Microbiol 1997;35:139-143.
29. Pujol I, Guarro J, Llop C, et al. Comparison study of broth macrodilution and microdilution antifungal susceptibility tests for the filamentous fungi. Antimicrob Agents Chemother 1996;40:2106-2110.
30. Hamilton-Miller JT, Shah S, Smith C. Silver sulphadiazine: a comprehensive in vitro reassessment. Chemotherapy 1993;39:405-409.
31. Hamilton-Miller JM, Shah S. A microbiological assessment of silver fusidate, a novel topical antimicrobial agent. Int J Antimicrob Agents 1996;6:97-99.
32. Brooks DE, Andrew SE, Dillavou CL, et al. Antimicrobial susceptibility patterns of fungi isolated from horses with ulcerative keratomycosis. Am J Vet Res 1998;59:138-142.
33. O'Day DM, Ray WA, Robinson RD, et al. In vitro and in vivo susceptibility of Candida keratitis to topical polyenes. Invest Ophthalmol Vis Sci 1987;28:874-880.
34. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-958.
35. Espinel-Ingroff A. Clinical relevance of antifungal resistance. Infect Dis Clin North Am 1997;11:929-944.
36. Espinel-Ingroff A. Clinical utility of in vitro antifungal susceptibility testing. Rev Esp Quimioter 2000;13:161-166.
37. O'Day DM, Ray WA, Robinson RD, et al. Correlation of in vitro and in vivo susceptibility of Candida albicans to amphotericin B and natamycin. Invest Ophthalmol Vis Sci 1987;28:596-603.
38. Stiller RL, Bennett JE, Scholer HJ, et al. Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis 1983;147:1070-1077.
39. Rex JH, Pfaller MA, Rinaldi MG, et al. Antifungal susceptibility testing. Clin Microbiol Rev 1993;6:367-381.
40. Pfaller MA, Rinaldi JN, Galgiani MS, et al. Multicenter evaluation of four methods of yeast inoculum preparation. J Clin Microbiol 1988;26:1437-1441.
41. Cook RA, McIntyre KA, Galgiani JN. Effects of incubation temperature, inoculum size, and medium on agreement of macro- and microdilution broth susceptibility test results for yeasts. Antimicrob Agents Chemother 1990;34:1542-1545.
42. Ford MM. Antifungals and their use in veterinary ophthalmology. Vet Chin North Am Small Anim Pract 2004;34:669-691.
43. O'Day DM, Head WS, Robinson RD, et al. Corneal penetration of topical amphotericin Band natamycin. Curr Eye Res 1986;5:877-882.
44. Behrens-Baumann W. Topical antimycotics in ophthalmology Ophthalmologica 1997;211:33-38.
45. Andrew SE, Brooks DE, Smith PJ, et al. Equine ulcerative keratomycosis: visual outcome and ocular survival in 39 cases (1987-1996). Equine Vet J 1998;30:109-116.
46. Kalavathy CM, Parmar P, Kailamurthy J, et al. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea 2005;24:449-452.
47. Ziogas BN, Sisler HD, Lucas WR. Sterol content and other characteristics of pimaricin-resistant mutants of Aspergillus nidulans. Pestic Biochem Physiol 1983;20:320-329.
48. Kantarcioglu AS, Yucel A. In vitro activities of terbinafine, itraconazole, and amphotericin B against Aspergillus and Cladosporium species. J Chemother 2002;14:562-567.